The "Normal" Cholesterol Myth: Detecting the Widowmaker Before It Strikes

Heart disease is still the #1 killer worldwide, yet 50-75% of people who suffer a heart attack have "normal" cholesterol levels. Traditional cardiology wa…

Published December 20, 202559:59The Longevity Show

Dr. John Osborne is a preventive cardiologist and clinical lipidologist in Dallas–Fort Worth, with an MD and PhD in cardiovascular physiology, training at Harvard and Brigham and Women's, and board certification in both cardiovascular disease and clinical lipidology — a combination roughly a hundred physicians in the country hold. He is also, by his own description, a rare bird: of about 33,000 US cardiologists, roughly 600 are preventive.

His argument is deliberately provocative. Between 50 and 75% of people who have a heart attack have normal or guideline-acceptable cholesterol. His explanation is not that we lack treatments — he claims we effectively have the cure — but that we never look for the disease. We wait for chest pain, a failed stress test, or sudden death, then treat the survivors. He calls the missing step the cardiac colonoscopy.

Most of the conversation is about which tests are worth doing, and he is blunt that the standard cardiology workup is not. Dr. Lin, who has been through that workup herself more than once and whose father needed a heart transplant, presses him on what patients should ask for instead, what it costs, and how much damage can actually be undone.

Before you watch

Osborne's central claim: the tools to stop, quantify and reverse plaque already exist, and the failure is detection. We screen for colon, breast and lung cancer, but we have no equivalent early-detection pathway for the disease that kills more people than the next seven causes combined.
He argues three standard tests offer little for plaque detection. EKGs are excellent for electrical problems and near useless for plumbing. Stress tests only detect blockages from about 70% narrowing, with 25–40% false negative and 25–40% false positive rates. And a heart cath — invasive, roughly $20,000, performed 2.5 million times a year in the US — only shows the donut hole, not the donut.
The plaques that kill are not the ones that cause symptoms. Vessels warehouse cholesterol in the wall and expand outward, sometimes doubling in size before ever narrowing inward. The lipid-rich plaques that rupture — what Osborne calls the lava — often narrow the vessel only 20–30%, which is why you can pass a stress test one week and have a heart attack the next.
There is only one normal calcium score, and it is zero. Osborne is pointed about the phrase 'a low score' — he compares it to telling someone they have a little bit of lung cancer. A non-zero CAC is the tip of the iceberg: it shows stabilised calcified plaque while remaining blind to the lipid-rich plaque and to narrowings.
The resolution difference is large. A calcium score takes 60–70 slices without contrast; cardiac CT takes around 1,600 paper-thin slices with contrast, revealing hard plaque, soft plaque, blockages, and incidentally the lungs, liver, spleen and even bone density from the thoracic spine.
AI is what makes soft plaque measurable. The human eye distinguishes roughly 50 shades of grey; CT voxels encode over 2,000. That allows quantification down to a tenth of a cubic millimetre — about a tenth the size of a full stop — which is what makes tracking whether plaque is progressing or regressing possible at all.
The pricing is backwards. Medicare reimburses cardiac CT at around $378 against roughly $20,000 for a heart cath and several hundred to several thousand for stress testing. Osborne is direct that reimbursement, training inertia, and who employs most cardiologists all shape which test you are offered.
Two independent factors decide whether cholesterol becomes plaque: the cholesterol itself, and whether your vessels are sticky. He describes the extremes as Velcro versus Teflon. The big modifiable stickiness drivers are nicotine in any form — smoked, chewed, patched, it is the nicotine activating endothelial receptors — plus high blood pressure, diabetes and pre-diabetes, and systemic inflammatory conditions like psoriasis, lupus and rheumatoid arthritis.
Reversal is real and quantifiable. Once the right tools are on board, Osborne reports lipid-rich plaque typically reducing by 20–30% over a few years — faster than it accumulated, since plaque is usually 20–30 years in the making. He describes a patient whose plaque kept progressing at an ApoB of 40 until adding a PCSK9 inhibitor and colchicine finally turned it around.
Colchicine earned FDA approval for cardiovascular risk reduction in June 2023, cutting events by about 31% without touching cholesterol, blood pressure or glucose. His sequence is deliberate: scan first for ground truth, address lipids and lifestyle, then check hs-CRP — and add colchicine if inflammation remains high, or if plaque progresses despite everything else.
On statins, Osborne is unambiguous that they are the most exhaustively studied drug in history and that the mitochondrial-poison framing is not supported by any data. But he is equally clear that they are one tool among many now — if they don't suit you, the non-statin toolbox is large, and refusing them is not a dead end.

Chapters

0:00

The Mission: Eliminating Heart Disease in Our Lifetime

Questions

My cholesterol is normal. Why would I need imaging?

Because between 50 and 75% of people who have a heart attack have normal or guideline-acceptable cholesterol. Osborne's framing is that blood levels tell you what is floating in the bloodstream, not what is being deposited in the wall — and he has seen people with high LDL and no plaque alongside people with pristine panels and extensive disease. His position is that blood tests become genuinely useful after imaging establishes whether the disease is there, because then you know which numbers are actually your targets.

I passed a stress test. Am I in the clear?

Not necessarily, and this is his sharpest point. Stress tests only start detecting blockages around 70% narrowing, with false negative rates of 25–40%. Meanwhile the plaques that rupture and cause heart attacks often narrow the vessel just 20–30% — not enough to cause symptoms or fail the test. That is the mechanism behind 'I felt fine, my stress test was normal last week.'

What should I actually ask for, and when?

Society of Cardiovascular CT guidelines suggest starting to look for plaque at 40, earlier with risk factors like smoking, diabetes, family history or high cholesterol. On bloods, Osborne wants a standard lipid panel plus ApoB, which he calls a sharper scalpel for all the harmful particles, plus a once-in-a-lifetime Lp(a). If you are offered an EKG, echo and stress test as a plaque workup, his advice is to recognise that as twentieth-century cardiology.

Why does he say everyone needs an Lp(a) test?

Because it is roughly six times more potent than ordinary cholesterol at forming plaque — sticky, clot-promoting and inflammatory — it is essentially 100% genetic, it affects about one in five people, and it does not appear on a standard panel unless specifically ordered. Around 80% of people will come back normal and can stop thinking about it. The National Lipid Association, on whose board Osborne has served, recommends everyone have it checked once.

What does he think about high cholesterol on keto or carnivore diets?

He deliberately declines to give a clean answer, which is worth noting given how confidently both camps argue this. He understands the hypothesis — high circulating cholesterol may matter less if your vessels are Teflon rather than Velcro — and says the science is not settled. His counterweight is a century of familial hypercholesterolaemia data showing that genetically high cholesterol produces enormous risk even in people who do everything right, and his suspicion that Teflon wears away eventually. Dr. Lin's own position is that she expects to trip up at some point, so lowering the exposure is the safer bet.

Are stem cells useful for heart disease?

Not yet, on his read. Most of the research has targeted cardiomyopathy rather than atherosclerosis, and after roughly 30 years of trying, he says none of it has paid off in a way that meets his evidence threshold — a few thousand people, randomised, followed for years. He shared one striking anecdote of a patient with severe heart failure who improved dramatically after stem cell therapy abroad, while being explicit that an n of one is not evidence.

The Longevity Letter